Payment overview · 2025
General Payments
$3,807.70
187 reported records · 36 companies
Healthcare provider profile · identity verified
Mathew Andrew Tilson, APNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MILWAUKEE, WI · NPI 1467763813
Verified facts
What the public records show
CMS Open Payments records show Mathew Andrew Tilson, APNP received $3,807.70 in general payments during 2025 across 187 reported records.
ABBVIE INC. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Ingrezza, Jardiance, Kerendia, Linzess, Mounjaro, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $790.13 | 20.8% | 55 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $343.92 | 9.0% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $274.77 | 7.2% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $263.07 | 6.9% | 13 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $198.16 | 5.2% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $172.06 | 4.5% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $163.51 | 4.3% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $134.22 | 3.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $132.82 | 3.5% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $130.71 | 3.4% | 5 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $101.14 | 2.7% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $86.97 | 2.3% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $70.95 | 1.9% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $66.84 | 1.8% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$66.74 | 1.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $65.68 | 1.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $64.49 | 1.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $62.66 | 1.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $52.14 | 1.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $49.19 | 1.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.93 | 1.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.04 | 1.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.77 | 1.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.98 | 1.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $37.94 | 1.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.72 | 1.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.27 | 0.9% | 2 | 2025 |
| Liquidia Technologies, Inc. | Unresolved — no canonical attribution shown | $32.47 | 0.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $31.21 | 0.8% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $31.08 | 0.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $26.89 | 0.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.72 | 0.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.50 | 0.6% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $21.66 | 0.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.99 | 0.6% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $15.36 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,696.21 | 186 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $292.43 | 17 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $263.85 | 20 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $198.16 | 10 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $188.14 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $163.75 | 9 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $159.48 | 10 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $151.80 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $132.82 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $131.94 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $130.71 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $101.93 | 7 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $101.14 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.86 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $91.72 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $86.97 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $72.85 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $72.85 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $66.84 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $66.74 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $65.68 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $64.49 | 3 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $56.41 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $52.14 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $50.26 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $49.19 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $48.93 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.77 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.77 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.07 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $37.94 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.27 | 2 | 2025 |
Source payment records
|
|||||
| YUTREPIA Normalized: yutrepia |
Drug | Liquidia Technologies, Inc. | $32.47 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $31.21 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $31.08 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $26.89 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $26.84 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| CERDELGA Normalized: cerdelga |
Drug | GENZYME CORPORATION | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| CEREZYME Normalized: cerezyme |
Biological | GENZYME CORPORATION | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $6.58 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $4.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 136 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 154 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 178 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 47 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
154 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
178 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 27 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 577 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 481 | 101 |
| Gabapentin | Gabapentin | 445 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 441 | 99 |
| Tizanidine Hcl | Tizanidine Hcl | 333 | 76 |
| Trazodone Hcl | Trazodone Hcl | 329 | 69 |
| Furosemide | Furosemide | 303 | 68 |
| Meloxicam | Meloxicam | 296 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 249 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 236 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 49 |
| Mounjaro | Tirzepatide | 178 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 46 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 174 | 43 |
| Potassium Chloride | Potassium Chloride | 171 | 39 |
| Linzess | Linaclotide | 154 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 27 |
| Jardiance | Empagliflozin | 147 | 33 |
| Clonidine Hcl | Clonidine Hcl | 136 | 22 |
| Eliquis | Apixaban | 136 | 27 |
| Prednisone | Prednisone | 136 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 33 |
| Lisinopril | Lisinopril | 127 | 35 |
| Metformin Hcl | Metformin Hcl | 127 | 29 |
| Montelukast Sodium | Montelukast Sodium | 127 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 121 | 24 |
| Omeprazole | Omeprazole | 116 | 27 |
| Losartan Potassium | Losartan Potassium | 114 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 24 |
| Carvedilol | Carvedilol | 99 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 17 |
| Simvastatin | Simvastatin | 94 | 24 |
| Mirtazapine | Mirtazapine | 90 | 17 |
| Azithromycin | Azithromycin | 86 | 64 |
| Donepezil Hcl | Donepezil Hcl | 85 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 82 | 24 |
| Doxepin Hcl | Doxepin Hcl | 82 | 16 |
| Tramadol Hcl | Tramadol Hcl | 82 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | suppressed |
| Olanzapine | Olanzapine | 72 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 11 |
| Promethazine Hcl | Promethazine Hcl | 67 | 40 |
| Spironolactone | Spironolactone | 61 | 17 |
| Valsartan | Valsartan | 61 | 16 |
| Alcohol Pads | Alcohol Antiseptic Pads | 59 | suppressed |
| Ezetimibe | Ezetimibe | 58 | 12 |
| Methylprednisolone | Methylprednisolone | 58 | 56 |
| Allopurinol | Allopurinol | 56 | 13 |
| Atenolol | Atenolol | 55 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 11 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Metformin Hcl Er | Metformin Hcl | 51 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | 12 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | suppressed |
| Nystatin | Nystatin | 47 | 23 |
| Vraylar | Cariprazine Hcl | 47 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 46 | suppressed |
| Risperidone | Risperidone | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Ozempic | Semaglutide | 39 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 12 |
| Alendronate Sodium | Alendronate Sodium | 38 | 12 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 16 |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 21 | suppressed |
| Klor-Con | Potassium Chloride | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Kerendia | Finerenone | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,807.70 · 187 records | ABBVIE INC. | ACTHAR, AIRSUPRA, AREXVY, AUSTEDO XR, AVYCAZ, Arikayce, Auvelity, CAMZYOS, CAPLYTA, CERDELGA, CEREZYME, CREON, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, FABRAZYME, FANAPT, FASENRA, GEMTESA, GVOKE HYPOPEN, INGREZZA, INSPIRE, JARDIANCE, KISUNLA, Kerendia, LEQVIO, LINZESS, LifeVest, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, SHINGRIX, SPRAVATO, SUBLOCADE, SYMPLICITY G3, TEFLARO, TERLIVAZ, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, WAKIX, Wegovy, YUPELRI, YUTREPIA, ZAVZPRET, ZEPBOUND, ZORYVE, Zubsolv | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error